Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19

• Main Authors: Yang Yi (Author), Meng Zhang (Author), Heng Xue (Author), Rong Yu (Author), Yang-Oujie Bao (Author), Yi Kuang (Author), Yue Chai (Author), Wen Ma (Author), Jing Wang (Author), Xiaomeng Shi (Author), Wenzhe Li (Author), Wei Hong (Author), Junhua Li (Author), Elishiba Muturi (Author), Hongping Wei (Author), Joachim Wlodarz (Author), Szczepan Roszak (Author), Xue Qiao (Author), Hang Yang (Author), Min Ye (Author)
• Format: Book
• Published: Elsevier, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

It is an urgent demand worldwide to control the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) are key targets to discover SARS-CoV-2 inhibitors....